NL-OMON51420招募中4 期
Subcutaneous vedolizumab drug de-escalation using therapeutic drug monitoring in inflammatory bowel disease: a randomized controlled pilot study - SILVER-study
Amsterdam UMC0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •patients with inflammatory bowel diseases in remission on a stable dose of
- •subcutaneous vedolizumab
排除标准
- •presence of anti-drug antibodies against vedolizumab, usage of
- •glucocorticosteroid, active draining peri-anal fistula or imminent need for
- •IBD-related surgery
研究者
相似试验
进行中（未招募）
1 期
engthening of vedolizumab injections based on drug concentrations in patients with inflammatory bowel diseaseEUCTR2022-000837-17-NLAmsterdam UMC40
招募中
4 期
Subcutaneous Interval Lengthening of Vedolizumab for Economic ResearchInflammatory Bowel DiseasesNCT06584162Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)40
招募中
不适用
Monitoring of Vedolizumab Infusion Therapy response with fecal calprotectin, ultrasound and trough serum level in Ulcerative colitis. A multicentric, prospective non-interventional StudyK51Ulcerative colitisDRKS00014249Internistische Gemeinschaftspraxis50
已完成
不适用
Therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel diseaseNL-OMON55193Maxima Medisch Centrum160
尚未招募
不适用
Therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel diseaseNL-OMON28041one160